LOTTE BIOLOGICS has begun construction on a $𝟑.𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲 𝐢𝐧 𝐈𝐧𝐜𝐡𝐞𝐨𝐧, 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚, as part of its goal to become a 𝐭𝐨𝐩 𝟏𝟎 𝐂𝐃𝐌𝐎 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞. The new site will cover over 𝟐.𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐪𝐮𝐚𝐫𝐞 𝐟𝐞𝐞𝐭 and feature three production plants with a total 𝐜𝐚𝐩𝐚𝐜𝐢𝐭𝐲 𝐨𝐟 𝟑𝟔𝟎,𝟎𝟎𝟎 𝐥𝐢𝐭𝐞𝐫𝐬. This flagship project underscores Lotte’s ambitious growth plans in the CDMO industry. https://lnkd.in/gkeE9SEr #Biopharma #Manufacturing #CDMO #Biotech #SouthKorea
Global Life Science Hub
Staffing and Recruiting
Multidiscipline headhunting firm providing comprehensive consultancy services to the Pharma and Medical Device industry.
About us
With over 20 years of experience across our senior leadership team, The Global Life Science Hub provides functional services and consulting with a solid mission to accelerate, strengthen and enhance global clinical trials. Financially backed by a global specialist head-hunting firm. We are primed to continue the growth and development in the Clinical, Regulatory Quality, Manufacturing and Biometrics sectors to effectively expand our functional services globally. The Global Life Science Hub strives to ensure that all of our clinical research clients can meet their end-point goals by providing a better alternative to recruitment agencies, CROs, CDMOs and other 3rd party vendors.
- Website
-
http://www.glshub.com
External link for Global Life Science Hub
- Industry
- Staffing and Recruiting
- Company size
- 2-10 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- recruitment, pharmaceuticals, life science, hiring, clinical research, biometrics, project management, central lab, CRO, Pharma, biotech, CRA, clinical research associate, clinical trial management, Manufacturing, Production, Regulatory, Quality, Quality Assurance, and Quality Control
Locations
-
Primary
London, GB
-
901 4th St N
St Petersburg, Florida 33701, US
Employees at Global Life Science Hub
-
Christopher Antoniou
CEO & Founder of Global Life Science Hub - Life Sciences Industry Expert
-
Alexander Antoniou
CEO & Founder of AL Solutions - Headhunting Senior Executives, Life Sciences - USA & EMEA
-
Zeliha Y.
Şu okulda öğrenci: Uludağ Üniversitesi
-
Kayleigh Stephens
Accounts & Operations Manager at AL Solutions
Updates
-
SciRhom, a German biotech company, has 𝐬𝐞𝐜𝐮𝐫𝐞𝐝 €𝟔𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐒𝐞𝐫𝐢𝐞𝐬 𝐀 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 to advance its monoclonal antibody, SR-878, into a first-in-human trial later this year. The trial, starting in 𝐀𝐮𝐬𝐭𝐫𝐢𝐚, will test the antibody for autoimmune diseases like 𝐫𝐡𝐞𝐮𝐦𝐚𝐭𝐨𝐢𝐝 𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬. The funding will support the program through 2027. https://lnkd.in/e-Xxc42v #Biotech #LifeSciences #Pharma #AutoimmuneDisease #VentureCapital
SciRhom secures €63M Series A for autoimmune disease program
https://endpts.com
-
Eli Lilly and Company 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐝 𝐩𝐥𝐚𝐧𝐬 𝐭𝐨 𝐚𝐜𝐪𝐮𝐢𝐫𝐞 Morphic Therapeutic 𝐟𝐨𝐫 $𝟑.𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐜𝐚𝐬𝐡, 𝐦𝐚𝐫𝐤𝐢𝐧𝐠 𝐢𝐭𝐬 𝐟𝐢𝐫𝐬𝐭 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐭𝐡𝐢𝐬 𝐲𝐞𝐚𝐫. This deal, offering a 79% premium on Morphic's closing price, will enhance Lilly's pipeline with Morphic’s experimental oral integrin drugs for autoimmune and other chronic diseases, including two Phase 2 trials for ulcerative colitis and Crohn’s disease. #PharmaAcquisition #BiotechNews #HealthcareInnovation #AutoimmuneDisease #EliLilly https://lnkd.in/eDxiemgA
Lilly discloses its first biotech acquisition of the year, buying Morphic for $3.2B
https://endpts.com
-
Happy Fourth of July to our US network! ✨ Enjoy the celebrations! #IndependenceDay #FourthOfJuly #CelebrateFreedom #Happy4thofJuly
-
-
GSK has restructured its deal with CureVac, 𝐩𝐚𝐲𝐢𝐧𝐠 $𝟒𝟐𝟗 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐮𝐩𝐟𝐫𝐨𝐧𝐭 𝐭𝐨 𝐠𝐚𝐢𝐧 𝐟𝐮𝐥𝐥 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐨𝐟 𝐭𝐡𝐞𝐢𝐫 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐯𝐞 𝐦𝐑𝐍𝐀 𝐢𝐧𝐟𝐥𝐮𝐞𝐧𝐳𝐚 𝐚𝐧𝐝 𝐂𝐨𝐯𝐢𝐝 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞𝐬. This strategic move allows GSK to take over all development and commercialization responsibilities for these vaccines, previously shared with CureVac. In tandem with this deal, 𝐂𝐮𝐫𝐞𝐕𝐚𝐜 𝐢𝐬 𝐥𝐚𝐲𝐢𝐧𝐠 𝐨𝐟𝐟 𝟑𝟎% 𝐨𝐟 𝐢𝐭𝐬 𝐰𝐨𝐫𝐤𝐟𝐨𝐫𝐜𝐞 as it shifts focus back to early-stage technology innovation and preclinical vaccine programs. This realignment is part of CureVac’s effort to optimize its operations and financial stability, extending its runway to 2028. Despite these changes, CureVac will continue to pursue its oncology pipeline, aiming to bring additional vaccines into human trials by 2025. https://lnkd.in/d34hzerx #Healthcare #Vaccines #Biotech #Pharma #mRNA
GSK licenses full rights to CureVac’s flu, Covid mRNA vaccines for $429M in restructured collaboration
https://endpts.com
-
SK bioscience 𝐡𝐚𝐬 𝐚𝐜𝐪𝐮𝐢𝐫𝐞𝐝 𝐚 𝟔𝟎% 𝐬𝐭𝐚𝐤𝐞 𝐢𝐧 𝐆𝐞𝐫𝐦𝐚𝐧 𝐜𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐞𝐫 IDT Biologika 𝐟𝐨𝐫 $𝟐𝟒𝟒 𝐦𝐢𝐥𝐥𝐢𝐨𝐧, marking a significant step in its global expansion strategy, "SKBS 3.0." This acquisition enhances SK's capabilities in 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 and positions it for growth in developed markets and new bio areas like 𝐚𝐧𝐭𝐢-𝐜𝐚𝐧𝐜𝐞𝐫 𝐯𝐢𝐫𝐮𝐬𝐞𝐬 𝐚𝐧𝐝 𝐜𝐞𝐥𝐥 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲. The deal, which follows SK's $𝟏.𝟑𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐈𝐏𝐎 𝐢𝐧 𝟐𝟎𝟐𝟏, 𝐛𝐨𝐨𝐬𝐭𝐞𝐝 𝐢𝐭𝐬 𝐬𝐡𝐚𝐫𝐞 𝐩𝐫𝐢𝐜𝐞 𝐛𝐲 𝟖%. IDT Biologika, with operations in 𝐆𝐞𝐫𝐦𝐚𝐧𝐲 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐔.𝐒., had record revenues in 2022 but saw a decline in 2023. https://lnkd.in/e9zNRb45 #PharmaNews #Biotech #GlobalExpansion #VaccineProduction #HealthcareInnovation
SK Bioscience begins 'globalization' push, paying $244M for majority stake in contract manufacturer IDT Biologika
fiercepharma.com
-
Samsung Biologics 𝐡𝐚𝐬 𝐬𝐞𝐜𝐮𝐫𝐞𝐝 𝐚 $𝟏.𝟎𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐜𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐰𝐢𝐭𝐡 𝐚𝐧 𝐮𝐧𝐧𝐚𝐦𝐞𝐝 𝐥𝐚𝐫𝐠𝐞 𝐔𝐒 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐦𝐩𝐚𝐧𝐲, marking its fourth major contract this year. This significant deal constitutes nearly 𝟒𝟎% 𝐨𝐟 𝐒𝐚𝐦𝐬𝐮𝐧𝐠 𝐁𝐢𝐨'𝐬 𝟐𝟎𝟐𝟑 𝐭𝐨𝐭𝐚𝐥 𝐬𝐚𝐥𝐞𝐬, 𝐰𝐡𝐢𝐜𝐡 𝐬𝐭𝐨𝐨𝐝 𝐚𝐭 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 $𝟐.𝟖 𝐛𝐢𝐥𝐥𝐢𝐨𝐧. Despite the biopharma downturn, the company has managed to report exceptional revenue. The contract, effective until the end of 2030, remains confidential regarding the company's identity and manufacturing details. Additionally, Samsung Bio recently expanded its deals with Baxter International Inc., Eli Lilly and Company, and Merck, reflecting its ongoing efforts to boost its manufacturing capabilities with new sites coming online soon. https://lnkd.in/esH_MdYy #PharmaNews #Biotech #Pharmaceuticals #HealthcareInnovation #ManufacturingIndustry
Samsung Bio pulls in $1.06B manufacturing deal with unnamed US pharma company
https://endpts.com
-
Alumis, an 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 on the cusp of 𝐏𝐡𝐚𝐬𝐞 𝟑, has secured $𝟐𝟓𝟎𝐌 𝐢𝐧 𝐚 𝐬𝐡𝐫𝐮𝐧𝐤𝐞𝐧 𝐈𝐏𝐎. The Bay Area startup sold 𝟏𝟑.𝟏𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 𝐚𝐭 $𝟏𝟔 𝐞𝐚𝐜𝐡 to fund the late-stage testing of its lead 𝐓𝐘𝐊𝟐 𝐝𝐫𝐮𝐠, studies of a second asset in neuroinflammatory conditions, and preclinical projects. While the IPO was smaller than initially projected, an additional 𝟐.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 were sold in a concurrent private placement. With $𝟑𝟒𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐥𝐥𝐨𝐜𝐚𝐭𝐞𝐝 toward clinical development, Alumis aims to create a next-gen immunology treatment, facing competition from Bristol Myers Squibb’s Sotyktu and Takeda’s TAK-279. Alumis has spent heavily on R&D, with $𝟏𝟑𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫 𝐚𝐧𝐝 $𝟏𝟎𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐. The company, led by Martin Babler, hopes to buck the trend of biotechs trading below their IPO price. https://lnkd.in/eK_H6kda #Biotech #Immunology #IPO #Pharma #HealthcareInnovation
Immunology biotech Alumis secures $250M in shrunken IPO
https://endpts.com
-
Curie.Bio, a biotech accelerator based in Cambridge, MA, has 𝐬𝐞𝐜𝐮𝐫𝐞𝐝 $𝟑𝟖𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐭𝐨 𝐛𝐨𝐥𝐬𝐭𝐞𝐫 𝐒𝐞𝐫𝐢𝐞𝐬 𝐀 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 for startups that graduate from its program. This significant funding boost, disclosed on Wednesday, elevates the firm’s total capital to nearly $𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧. Led by Alexis Borisy, Zach Weinberg, and Christoph Lengauer, Curie.Bio allocates these funds primarily to support emerging drug developers in reaching clinical stages. Notably, the firm has a diverse 20-startup portfolio and aims for investments with blockbuster potential, targeting at least $𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐩𝐞𝐚𝐤 𝐬𝐚𝐥𝐞𝐬. Curie.Bio’s model involves investing $5-7 million in seed rounds, taking about a 7% stake, and providing extensive R&D services to help startups progress efficiently. https://lnkd.in/ehEaPru2 #Biotech #StartupFunding #SeriesA #PharmaInnovation #VCFunding
Alexis Borisy and Zach Weinberg’s Curie.Bio secures $380M to support portfolio’s Series A rounds
https://endpts.com
-
Foresite Capital 𝐡𝐚𝐬 𝐫𝐚𝐢𝐬𝐞𝐝 $𝟗𝟎𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐟𝐨𝐫 𝐢𝐭𝐬 𝐬𝐢𝐱𝐭𝐡 𝐟𝐮𝐧𝐝, 𝐚𝐢𝐦𝐢𝐧𝐠 𝐭𝐨 𝐜𝐚𝐩𝐢𝐭𝐚𝐥𝐢𝐳𝐞 𝐨𝐧 𝐰𝐡𝐚𝐭 𝐂𝐄𝐎 Jim Tananbaum, M.D., describes as "one of the best biotech investment environments" of his career. This new fund will continue Foresite's strategy of backing drug developers and companies at the intersection of technology and biotechnology. Focusing on 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, 𝐥𝐢𝐟𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐢𝐧𝐟𝐫𝐚𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞, 𝐚𝐧𝐝 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲, Foresite has invested in biotechs like Alumis, Latigo Biotherapeutics, Inc. , and Xaira Therapeutics, 𝐰𝐡𝐢𝐜𝐡 𝐡𝐚𝐯𝐞 𝐜𝐨𝐥𝐥𝐞𝐜𝐭𝐢𝐯𝐞𝐥𝐲 𝐫𝐚𝐢𝐬𝐞𝐝 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 $𝟏𝟑𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐧𝐝 $𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐭𝐡𝐢𝐬 𝐲𝐞𝐚𝐫. These investments highlight Foresite's presence in significant private funding rounds and its role in facilitating the transition from private investments to public markets. https://lnkd.in/e5ZHtpzT #BiotechInvestment #VentureCapital #HealthcareInnovation #LifeSciences #PrecisionMedicine
Foresite raises $900M to make big bets in 'one of the best biotech investment environments'
fiercebiotech.com